| 68Ga-PSMA-11 PET/CT | Gallium-68-PSMA-11 positron emission tomography/computed tomography |
| 177Lu | Lutetium-177 |
| 177Lu-PSMA I&T | 177Lu-DOTAGA-(I-y)fk(Sub-KuE) |
| ADT | Androgen deprivation therapy |
| AL | Acute leukaemia |
| EANM | European Association of Nuclear Medicine |
| EAU | European Association of Urology |
| EBRT | External beam radiotherapy |
| ECOG | European Cooperative Oncology Group |
| IRB | institutional review board |
| NCI-CTCAE | National Cancer Institute Common Terminology Criteria for Adverse Events |
| mCRPC | Metastatic castrate resistant prostate cancer |
| MDS | Myelodysplastic syndrome |
| OS | Overall survival |
| OR | odds ratio |
| PERCIST | PET response criteria in solid tumors |
| PET/CT | Gallium-68-PSMA-11 positron emission tomography/computed tomography |
| PCWG | Prostate Cancer Working Group |
| PFS | Progression-free survival |
| PSA | Prostate-specific antigen |
| PSMA | Prostate-specific membrane antigen |
| RLT | Radioligand therapy |